Onesource Specialty Pharma Earns 'Leader' ESG Rating from NSE

Onesource Specialty Pharma Ltd announced on April 16, 2026, that it has received an independent ESG rating of 73, placing it in the 'Leader' category for the financial year 2025. This assessment was provided by NSE Sustainability Ratings & Analytics Limited.

The rating was determined solely based on publicly available information, with no direct engagement from the company to the rating agency. This intimation is in compliance with SEBI Listing Regulations, underscoring the growing emphasis on ESG disclosures for listed companies.

Why This ESG Rating Matters

Achieving a 'Leader' ESG rating signals strong performance across Environmental, Social, and Governance factors. These ratings are increasingly influential in guiding investor decisions and shaping corporate reputation, demonstrating a commitment to sustainable business practices.

Company Background: From Stelis Biopharma to Specialty Pharma

Onesource Specialty Pharma, formerly known as Stelis Biopharma Limited, was listed on stock exchanges in January 2025. The company operates as a specialty pharmaceutical contract development and manufacturing organisation (CDMO), specializing in biologics and injectables.

Despite its capabilities, the company has faced financial challenges. In early 2026, Onesource shares fell 18% after reporting Q3 losses, partly due to a delay in Canadian approval for semaglutide, which affected revenue and margins. Further disclosures in early 2026 indicated that Tenshi Pharmaceuticals Private Limited had pledged additional equity shares, raising the total pledged shares to 8.06% of the company's capital.

Impact of the 'Leader' ESG Rating

• Enhanced Corporate Profile: A 'Leader' ESG rating can improve brand perception among investors, customers, and stakeholders.
• Investor Scrutiny: Increased focus on ESG metrics may lead to more informed investment decisions and higher expectations for sustainability performance.
• Data Transparency: The rating's basis on public data encourages the company to ensure its disclosures are comprehensive and accurate.
• Peer Benchmark: Provides a reference point for ESG performance within the Indian pharmaceutical sector.

Potential Risks and Considerations

• Rating Validity: Since the rating is based on public data without direct company input, it may not fully reflect the company's current practices or internal ESG initiatives.
• Sustaining Performance: Maintaining and improving this 'Leader' status will require continued focus and tangible actions on ESG fronts.
• Financial Pressures: Past financial performance, including revenue shortfalls and margin pressures, could affect resources available for ESG initiatives.

Peer Comparison in the Pharmaceutical Sector

Several Indian pharmaceutical companies are actively involved in ESG assessments. Cipla Limited received an 'Aspiring' ESG rating of 65/100 from NSE Sustainability in February 2026. In comparison, global pharma major Lupin Limited has secured high ratings, including a CDP 'A' for climate and water security and an S&P Global ESG score of 91 in 2025, positioning it as a leader in sustainability. Sun Pharma also publishes its ESG Overview for FY24-25, showing a trend towards greater ESG disclosure in the sector.

Key Rating Context

• The ESG rating of 73 was assigned for the financial year 2025.
• NSE Sustainability Ratings & Analytics Limited is SEBI-registered as a Category I ESG Rating Provider (ERP).
• NSE's ESG rating methodology is data-driven and materiality-based, aligning with national and international standards.

Next Steps for Investors and the Company

Investors and analysts will likely track:

• Future ESG rating cycles and any changes in Onesource's score and category.
• Company disclosures and initiatives related to Environmental, Social, and Governance improvements.
• Investor reactions and analyst reports referencing this ESG rating.
• How the company leverages this 'Leader' rating in its corporate communications and stakeholder engagement.
• The company's ability to sustain this performance amidst its operational and financial priorities.